Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series
Open Access
- 12 August 2024
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (11) , 4765-4771
Abstract
Bariatric surgery is increasingly performed to treat severe obesity. As a result of anatomical and physiological changes in the gastrointestinal tract, the pharmacokinetics (PK) of oral drugs can be altered, affecting their efficacy and safety. This includes the class of tyrosine kinase inhibitors (TKIs) which are used to treat chronic myeloid leukemia (CML). This case series describes the clinical course of four CML cases with a history of bariatric surgery. The patients used various TKIs (nilotinib, dasatinib, bosutinib, ponatinib, and imatinib) for which 15 drug levels were measured. The measured TKI concentrations were in part subtherapeutic, and highly variable when compared to mean levels measured in the general population. Multiple drug levels were measured in these patients, as the clinicians were aware of the possible impact of bariatric surgery. The drug levels were used as additional input for clinical decision-making. All four patients required TKI switches and/or dose modifications to achieve an effective and tolerable treatment. Eventually, adequate clinical and molecular remissions were achieved in all cases. In summary, TKI concentrations of patients undergoing bariatric surgery may be subtherapeutic. Moreover, there is substantial interindividual and intraindividual variation, which may be explained by the complex interference of bariatric surgery and associated weight loss. For clinical practice, therapeutic drug monitoring is advised in patients with a history of bariatric surgery in case of suboptimal response or loss of response.Keywords
This publication has 34 references indexed in Scilit:
- Association between bariatric surgery and outcomes in chronic myeloid leukemiaCancer, 2023
- Drug absorption in bariatric surgery patients: A narrative reviewHealth Science Reports, 2022
- Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux ExposuresJournal of Gastrointestinal Surgery, 2019
- Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case reportClinical Case Reports, 2019
- Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in OncologyClinical Pharmacology & Therapeutics, 2017
- Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemiaEuropean Journal of Clinical Pharmacology, 2012
- Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaCancer Chemotherapy and Pharmacology, 2012
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEuropean Journal of Clinical Pharmacology, 2011
- Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patientsCancer Chemotherapy and Pharmacology, 2011
- Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailabilityCancer Chemotherapy and Pharmacology, 2010